Georgetown simulation estimates 9.4 life years lost after the most cytotoxic breast cancer chemotherapy

Researchers at Georgetown University's Lombardi Comprehensive Cancer Center and colleagues used a population simulation model to estimate that women who received the most cytotoxic chemotherapy regimens for breast cancer lost on average 9.4 remaining life years, news-medical.net reports. The loss is attributed to earlier onset of aging-related diseases. The study was published on November 10, 2026, in JAMA Network Open. news-medical.netnews-medical.netnews-medical.netOpen source ↗

According to the authors, this is the first estimate of the lifetime balance between curing breast cancer and possible acceleration of biological aging using population-based simulation modeling. Female breast cancer survivors make up the largest single segment of the 18.6 million cancer survivors in the United States.

Model design and the p16 marker

The model was built on women aged 30 to 79 and compared chemotherapy types that caused more or less cellular damage and biological age acceleration. To estimate biological age over the remaining lifetime, the team used data on the relationship between chemotherapy and blood levels of the p16 protein, a common biomarker of senescence.

The authors chose p16 because published research provides good data on it and because laboratory evidence suggests that clearing p16-rich cells could extend lifespan. Other biological aging markers are being studied and could be used in future work. news-medical.netnews-medical.netnews-medical.netOpen source ↗

Lead author Swarnavo Sarkar explains that chemotherapy improves breast cancer survival but can also increase damage to normal tissues, including the number of senescent cells. These are damaged cells that have stopped dividing and resist cell death. According to Sarkar, they secrete molecules that cause aging-related diseases through added tissue damage and inflammation.

Duration of effects and next steps

Senior author Jeanne Mandelblatt, director of Georgetown Lombardi's Institute for Cancer and Aging Research, notes that chemotherapy-induced biological aging can persist for years and its effects may not be visible for many years. They may include frailty and cognitive problems.

Mandelblatt says treatment choices will always be based on the potential to cure. She hopes the model can guide studies of testing biological age after treatment, with the aim of personalized survivorship care. She adds that physical activity and medications used for other purposes show promise in slowing accelerated aging in cancer survivors, which may recoup the estimated loss; this was not tested in the study. news-medical.netnews-medical.netnews-medical.netOpen source ↗

The analysis was possible because both Mandelblatt and Sarkar belong to CISNET, a 25-year-old consortium of National Cancer Institute-sponsored investigators who use simulation modeling. The authors plan to extend the method to radiotherapy, immunotherapy, targeted and hormonal treatments, and to add survivor characteristics to inform conversations about individual outcomes.